Products
AFLIVIS 40 mg/ml sol inj 2 mg 1 pce

AFLIVIS 40 mg/ml sol inj 2 mg 1 pce

7680700620017 CH-70062 S01LA05 11.99.0.

Active substances:

Afliberceptum

No images available

Details

Product number: 7006201
CPT: -
Packaging group: 1
Unit: Fertigspritze(n)
Composition: afliberceptum 2 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum, natrii chloridum, polysorbatum 20, aqua ad iniectabile, ad solutionem pro 50 µl corresp. natrium 27 µg.

Articles (1)

Aflivis 40 mg/ml, Injektionslösung in einer Fertigspritze

Injektionslösung

View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance	Quantity	Type	Category
afliberceptum	2.0 MG	Substance	Wirkstoff (Principe actif)
natrii acetas trihydricus	-	Substance	HNIDK
acidum aceticum glaciale	-	Substance	HNIDK
saccharum	-	Substance	HNIDK
natrii chloridum	-	Substance	HNIDK
polysorbatum 20	-	Substance	HNIDK
aqua ad iniectabile	-	Substance	HNIDK
natrium	27.0 UG	Substance	HBESI

Authorization holder

OmniVision AG

8212 Neuhausen am Rheinfall

Authorization information

Swissmedic authorization number: 70062
Drug name: Aflivis, Injektionslösung in einer Fertigspritze
Galenic form: INLFS
ATC Code: S01LA05
Authorization status: Z
Dispensation category: B
First authorization: 02/02/2026
Authorization expiration date: 01/02/2031
IT number: 11.99.0.
Domain: Human medicine

Field of application

Exsudative (feuchte) altersbezogenen Makuladegeneration (AMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO), diabetisches Makulaödem (DME), Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Packaging details

Description (FR): AFLIVIS 40 mg/ml sol inj 2 mg 1 pce
Description (DE): AFLIVIS 40 mg/ml Inj Lös 2 mg 1 Stk
Market launch: 01/10/2026
Narcotic (BTM): No